Skip to Content
  • Previous Rank
    259
  • Revenues ($M)
    $39,498
  • Revenue Percent Change
    -6.5%
  • Profits ($M)
    $4,442
  • Profits Percent Change
    -62.7%
  • Assets ($M)
    $101,779
  • Employees
    68,000

Revenue for the 165-year-old drug maker slid 6.5% in 2015 largely due to currency fluctuations and divestitures. In the U.S., sales grew on the strong performance of its diabetes and cancer medications and as a result of its $8.3 billion acquisition of antibiotic maker Cubist Pharmaceuticals. The company also pressed ahead with restructuring efforts–it shed 2,000 jobs in 2015–and kept pace in the industry immunotherapy race, with the widening range of approved uses for Keytruda, Merck’s breakthrough immuno-oncology drug.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Kenneth C. Frazier
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, NJ
Employees68,000
Websitehttp://www.merck.com
Years on Global 500 List22

Merck Rank History

placeholder

Key Financials (last fiscal year)

($ Millions)% change
Revenues ($M)$39,498-6.5%
Profits ($M)$4,442-62.7%
Assets ($M)$101,779-
Total Stockholder Equity ($M)$44,676-

Profit Ratios

Profit as % of Revenues11.2%
Profits as % of Assets4.4%
Profits as % of Stockholder Equity9.9%